



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

		Complete if Known	
Application Number	09/529,053-Conf. #1413		
Filing Date	April 6, 2000		
First Named Inventor	James W. Waldman		
Art Unit	1617		
Examiner Name	S. Wang		
		Attorney Docket Number	28385/35415

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SW/	E1	Ashour et al., 5-(m-Benzylxybenzyl) barbituric Acid Acyclonucleoside, a Uridine Phosphorylase Inhibitor, and 2',3',5'-Tri-O-Acetyluridine, a Prodrug of Uridine, as Modulators of Plasma Uridine Concentration. Biochemical Pharmacology, Vol. 15, pp. 1601-1611 (1996)	
/SW/	E2	Hidalgo et al., Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients with Advanced Solid Malignancies, Journal of Clinical Oncology, Vol. 18, No. 1 pp. 167-177 (2000)	
/SW/	E3	Kelsen et al., Phase I Trial and PN401, an Oral Prodrug of Uridine, to Prevent Toxicity from Fluorouracil in Patients with Advanced Cancer, Journal of Clinical Oncology, Vol. 15, No. 4 pp. 1511-1517 (1997)	
/SW/	E4	Van Groeningen et al., Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine, Annals of Oncology 4:317-320 (1993)	
/SW/	E5	Van Groeningen et al., Clinical and Pharmacologic Study of Orally Administered Uridine , Journal of the National Cancer Institute, Vol. 83, No. 6, pp. 437-441 (1991)	
/SW/	E6	The Merck Index Eleventh Edition, Merck & Co., NJ (1989), pp. 437, 1480, 1554.	
/SW/	E7	Hawley's Condensed Chemical Dictionary Thirteenth Edition, Van Nostrand Reinhold, New York, NY (1997), pp. 329, 1105, 1159.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Shengjun Wang/	Date Considered	11/2/2009
--------------------	-----------------	-----------------	-----------